MDACC Study No:RTOG0912 ( NCT No: NCT01236547)
Title:A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Principal Investigator:Gary B. Gunn
Treatment Agent:Intensity Modulated Radiotherapy; Paclitaxel; Pazopanib; Placebo
Study Status:Open
Study Description:The goal of this clinical research study is to learn if adding pazopanib to
paclitaxel and radiation (chemoradiotherapy) is safe and tolerable.

Pazopanib is designed to block the growth of blood vessels that supply
nutrients needed for tumor growth. This may prevent or slow the growth of
cancer cells.

Paclitaxel is designed to block cancer cells from dividing, which may cause
them to die.
A placebo is not a drug. It looks like the study drug but is not designed to
treat any disease or illness. It is designed to be compared with a study drug
to learn if the study drug has any real effect.
Hide details for General InformationGeneral Information

Disease Group:Thyroid
Phase of Study:Phase II
Treatment Agents:Intensity Modulated Radiotherapy
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Radiation Therapy Oncology Group
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gary B. Gunn
Dept:Radiation Oncology
For Clinical Trial Enrollment:713-563-2300
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults